Want to see BRNS full AI Analyst Report?
BRNS Stock Chart & Stats
$0.60
>-$0.01(-0.33%)
At close: 4:00 PM EDT
$0.60
>-$0.01(-0.33%)
Day’s Range― - ―
52-Week Range$0.51 - $1.83
Previous CloseN/A
Volume5.81K
Average Volume (3M)124.73K
Market Cap
$24.24M
Enterprise Value-$22.31
Total Cash (Recent Filing)$59.30M
Total Debt (Recent Filing)$10.29M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Nov 05, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.00Price Target Upside900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet LeverageLow financial leverage gives Barinthus structural flexibility to fund clinical programs without high interest burden. For a development-stage biotech, limited debt reduces bankruptcy and fixed-cost risk, allowing management to prioritize R&D and pursue partnerships or equity raises with more optionality over months.
Decisive Shareholder Approval For Strategic TransactionOverwhelming shareholder backing for the Scheme of Arrangement creates procedural certainty around a strategic corporate change. That durable governance endorsement reduces transactional execution risk, enabling planned restructurings or partner negotiations that can reshape capital structure and long-term strategy.
Platform-focused Immunotherapy R&DA platform approach in immunotherapy supports multi-indication development and scalability of assets, enabling reusable science across programs. This structural R&D model can attract collaborators, allow efficient pipeline expansion, and sustain long-term value creation beyond any single asset outcome.
Bears Say
Zero Recent Revenue And Heavy Cash BurnThe company lacks recurring revenue and is consuming significant cash, with losses translating into real negative free cash flow. This creates structural funding needs over the medium term, increasing probability of dilution or dilutive financings and pressuring operational runway absent external capital or deal milestones.
Nasdaq Listing And Minimum-bid Compliance RiskFormal noncompliance and transfer to the Capital Market are durable governance/market-access risks: potential delisting or the need for corrective equity actions can limit liquidity, raise cost of capital, and deter institutional partners, compressing strategic options until compliance is restored.
Erosion Of Shareholder Equity And Negative ROEMaterial decline in shareholders' equity signals sustained value erosion from ongoing losses and past financings. Deeply negative returns on equity indicate the business is not generating residual capital, increasing reliance on external funding and reducing the buffer to absorb future R&D setbacks or financing stress.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.51 and its highest was $1.83 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $24.24M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 78 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Aug 06, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.02.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.25.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,848,892 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -0.877%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
BRNS Stock 12 Month Forecast
Average Price Target
$6.00
▲(900.00% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
―
Insiders
0.03% Mutual Funds
21.57% Other Institutional Investors
78.40% Public Companies and
Individual Investors